C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 May 28

PMID 35625314

Authors

Yichang Zhao

Chenlin Xiao

Jingjing Hou

Jiamin Wu

Yiwen Xiao

Bikui Zhang

Indy Sandaradura

Hong Luo

Jinhua Li

Miao Yan

Affiliations

Soon will be listed here.

Abstract

This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled from the intensive care unit. Factors affecting the meropenem trough concentration were analyzed, and a multiple linear regression model was constructed. Logistic regression analyses were used to investigate the relationship between Ctrough and clinical efficacy. A total of 64 patients were enrolled, in whom 210 meropenem concentrations were measured. Of the total, 60.9% (39/64) were considered clinically successful after treatment. Ctrough may increase with increased blood urea nitrogen, albumin, and concomitant antifungal use. By contrast, concentration may decrease with increased endogenous creatinine clearance rate. Six variables, including Ctrough/minimum inhibitory concentration (MIC) > 4, were associated with the efficacy of meropenem. There was an independent correlation between Ctrough/MIC > 4 and efficacy after fully adjusting for confounding factors. Based upon renal function indexes, it is possible to predict changes in meropenem concentration and adjust the dosage precisely and individually. Ctrough/MIC > 4 is a potential instrument to predict successful treatment with meropenem.

Citing Articles

Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.

Gatti M, Cojutti P, Pea F Crit Care. 2024; 28(1):123.

PMID: 38627763 PMC: 11020314. DOI: 10.1186/s13054-024-04911-5.

References

Nunes M, Filho A, Alvares V, Meneguz-Moreno R, Lamas E, Loures V . CKD-EPI versus Cockcroft-Gault formula for predicting contrast-induced nephropathy following percutaneous coronary intervention in patients without significant renal impairment. Rev Port Cardiol (Engl Ed). 2018; 37(1):25-33. DOI: 10.1016/j.repc.2017.05.009. View

Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C . Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother. 2018; 73(12):3413-3422. DOI: 10.1093/jac/dky370. View

Tam V, McKinnon P, Akins R, Rybak M, Drusano G . Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002; 50(3):425-8. DOI: 10.1093/jac/dkf130. View

Nguyen C, Do T, Bruggemann R, Ten Oever J, Kolwijck E, Adang E . Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. Int J Antimicrob Agents. 2019; 54(6):790-797. DOI: 10.1016/j.ijantimicag.2019.07.003. View

Chen C, Yan M, Hu C, Lv X, Zhang H, Chen S . Diagnostic efficacy of serum procalcitonin, C-reactive protein concentration and clinical pulmonary infection score in Ventilator-Associated Pneumonia. Med Sci (Paris). 2018; 34 Focus issue F1:26-32. DOI: 10.1051/medsci/201834f105. View

Porfyridis I, Georgiadis G, Vogazianos P, Mitis G, Georgiou A . C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia. Respir Care. 2013; 59(4):574-81. DOI: 10.4187/respcare.02741. View

Dhillon S . Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs. 2018; 78(12):1259-1270. PMC: 6132495. DOI: 10.1007/s40265-018-0966-7. View

Lan J, Wu Z, Wang X, Wang Y, Yao F, Zhao B . Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection. J Pharm Sci. 2022; 111(6):1833-1842. DOI: 10.1016/j.xphs.2022.01.015. View

Lanks C, Musani A, Hsia D . Community-acquired Pneumonia and Hospital-acquired Pneumonia. Med Clin North Am. 2019; 103(3):487-501. DOI: 10.1016/j.mcna.2018.12.008. View

10.

Muscedere J, Day A, Heyland D . Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis. 2010; 51 Suppl 1:S120-5. DOI: 10.1086/653060. View

11.

Kahlmeter G, Brown D, Goldstein F, MacGowan A, Mouton J, Odenholt I . European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect. 2006; 12(6):501-3. DOI: 10.1111/j.1469-0691.2006.01454.x. View

12.

De Waele J, Carrette S, Carlier M, Stove V, Boelens J, Claeys G . Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2013; 40(3):380-7. DOI: 10.1007/s00134-013-3187-2. View

13.

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

14.

Hartman S, Bruggemann R, Orriens L, Dia N, Schreuder M, de Wildt S . Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature. Clin Pharmacokinet. 2019; 59(2):173-205. PMC: 7007426. DOI: 10.1007/s40262-019-00813-w. View

15.

van Hasselt J, Rizk M, Lala M, Chavez-Eng C, Visser S, Kerbusch T . Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016; 81(6):1113-23. PMC: 4876184. DOI: 10.1111/bcp.12901. View

16.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand M . Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. Clin Infect Dis. 2017; 65(6):1033-1036. DOI: 10.1093/cid/cix443. View

17.

Mouton J, den Hollander J . Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994; 38(5):931-6. PMC: 188129. DOI: 10.1128/AAC.38.5.931. View

18.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

19.

Zhou Q, He B, Zhang C, Zhai S, Liu Z, Zhang J . Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging. 2011; 28(11):903-12. DOI: 10.2165/11595960-000000000-00000. View

20.

Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I . Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017; 72(10):2891-2897. DOI: 10.1093/jac/dkx209. View